Table 4.
Treatment in all included patients with juvenile Sjögren's syndromea
| No. | SGUS– | SGUS+ | P b | Benjamin‐Hochberg adjustment | |
|---|---|---|---|---|---|
| Symptomatic treatment, current | 29/59 (49)c | 17/25 (68) | 16/34 (47) | 0.109 | NS |
| Symptomatic treatment, ever | 47/59 (80)d | 22/25 (88) | 25/34 (74) | 0.172 | NS |
| Salivary substitutes, current | 4/59 (7) | 1/25 (4) | 3/34 (9) | 0.466 | NS |
| Salivary substitutes, ever | 5/59 (8) | 1/25 (4) | 4/34 (12) | 0.466 | NS |
| Lacrimal substitutes, current | 25/59 (42)e | 16/25 (64) | 9/34 (26) | 0.004 | Significant |
| Lacrimal substitutes, ever | 30/59 (51)e | 18/25 (72) | 12/34 (35) | 0.005 | Significant |
| NSAIDS, current | 9/59 (15) | 1/25 (4) | 8/34 (24) | 0.039 | NS |
| NSAIDs, ever | 25/59 (42)f | 9/25 (36) | 16/34 (47) | 0.396 | NS |
| Systemic treatment, ever | 56/59 (95)g | 25/25 (100) | 31/34 (91) | 0.127 | NS |
| Systemic treatment, current | 46/59 (78)h | 23/25 (92) | 23/34 (68) | 0.026 | NS |
| Hydroxychloroquine, ever | 54/59 (92)g | 25/25 (100) | 29/34 (85) | 0.045 | NS |
| Hydroxychloroquine, current | 40/59 (68)g | 22/25 (88) | 18/34 (53) | 0.004 | Significant |
| MTX, ever | 22/57 (39)f | 9/25 (36) | 13/32 (41) | 0.722 | NS |
| MTX, current | 14/57 (25)f | 6/25 (24) | 8/32 (25) | 0.931 | NS |
| Azathioprine, ever | 12/58 (21)i | 6/25 (24) | 6/33 (18) | 0.588 | NS |
| Azathioprine, current | 10/58 (17)j | 5/25 (20) | 5/33 (15) | 0.628 | NS |
| Low prednisone, ever | 31/57 (54)d | 11/24 (46) | 20/33 (61) | 0.269 | NS |
| Low prednisone, current | 12/57 (21)k | 4/24 (17) | 8/33 (24) | 0.489 | NS |
| High prednisone, ever | 13/59 (22)c | 6/25 (24) | 7/34 (21) | 0.755 | NS |
| High prednisone, current | 5/59 (8)j | 2/25 (8) | 3/34 (9) | 0.911 | NS |
Values are the number of patients with positive findings/patients with available information (%), unless indicated otherwise. Regional differences refer to patients included in Brazil compared to patients included in Europe/US. SGUS = salivary gland ultrasonography; NS = nonsignificant; NSAIDs = nonsteroidal antiinflammatory drugs; MTX = methotrexate.
P values are for the comparison of SGUS+ and SGUS– patients.
Six patients with systemic lupus erythematosus (SLE)/mixed connective tissue disease (MCTD), with regional differences.
Six patients with SLE/MCTD.
Five patients with SLE/MCTD, with regional differences.
One patient with SLE/MCTD.
Eight patients with SLE/MCTD.
Eight patients with SLE/MCTD, with regional differences.
Four patients with SLE/MCTD, with regional differences.
Four patients with SLE/MCTD.
Five patients with SLE/MCTD.